Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 92 posts found.

MHRA sign

Astellas prostate cancer drug gets third approval from MHRA

May 12, 2021
Research and Development Astellas, MHRA, cancer research, cancer treatment, pharma, pharma news, prostate cancer

The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making …

News
az

AstraZeneca to collaborate with Alchemab on prostate cancer research

May 6, 2021
AstraZeneca, prostate cancer

AstraZeneca have announced a new collaboration with Cambridge-based biotech company Alchemab, with the aim of accelerating prostate cancer research. Alchemab …

News

Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

March 31, 2020
Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …

News

Prostate Cancer becomes most commonly diagnosed cancer in England

January 28, 2020
Manufacturing and Production Cancer, Cancer diagnoses, NHS England, breast cancer, prostate cancer

Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest …

News
zytiga_outside

NHS Scotland recommends Janssen’s Zytiga combo for newly diagnosed prostate cancer

January 13, 2020
Sales and Marketing Cancer, NHS, Scotland, nhs scotland, prostate cancer

Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the …

News
smoking-1026556_1280

Largest drop ever in US cancer mortality rates, new study shows

January 9, 2020
Business Services Cancer, brain cancer, lung cancer, prostate cancer

The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline …

News
astrazeneca_plaque

AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals

December 20, 2019
Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer

AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …

News

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

News
merck-keytruda

Prostate Cancer ‘super responders’ could live for two more years on Keytruda

November 28, 2019
Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …

News

Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

October 1, 2019
Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …

News
janssen_latest_logo_on_sign_closer

FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer

September 19, 2019
Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer

Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …

News
astrazeneca_plaque

AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial

August 7, 2019
Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …

News
fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

News
8655563196_1c0f83c447_z

New urine test can diagnose and offer prognosis for prostate cancer

July 8, 2019
Sales and Marketing Cancer, oncology, pharma, prostate cancer, urine test

A new urine test can diagnose cases of aggressive prostate cancer more quickly than invasive biopsies. The test can also …

News
janssen_latest_logo_on_sign_closer

Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

June 3, 2019
Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025